Endo to provide fill-finish services for Novavax COVID-19 vaccine

By The Science Advisory Board staff writers

Par Sterile Products has entered a nonexclusive agreement with Novavax to provide fill-finish manufacturing services at its Rochester, MI, plant for Novavax's COVID-19 vaccine candidate.

Under the agreement, Par Sterile, a subsidiary of Endo International, has begun production of the NVX-CoV2373 final drug candidate, with initial batches to be used in Novavax's phase III clinical trial in the U.S. Par Sterile will also fill-finish vaccine intended for commercial distribution in the U.S.

NVX-CoV2373 is currently in multiple phase II clinical trials to evaluate safety and immunogenicity. Interim data is expected before the end of 2020. Novavax has secured $2 billion in funding for its global coronavirus vaccine program, including $388 million from the Coalition for Epidemic Preparedness Innovations (CEPI).

Financial and other terms of the agreement were not disclosed.

Copyright © 2020 scienceboard.net

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?